Entecavir and tenofovir are both anti-hepatitis B virus drugs, there is no saying who is better or worse.
Entecavir tablets, is indicated for the treatment of chronic adult hepatitis B with active viral replication, persistent elevation of serum alanine aminotransferase, or liver histology showing active lesions. It is also indicated for the treatment of nucleoside-primed pediatric patients 2 to <18 years of age with chronic HBV-infected compensated liver disease. However, it is contraindicated in persons who are hypersensitive to entecavir or any of the ingredients in the preparation.
Adverse reactions to the use of entecavir tablets include headache, fatigue, dizziness, and nausea. Adverse events commonly seen in lamivudine-treated patients are headache, fatigue, and vertigo. There may also or be allergic reactions of the immune system disorder type, adverse reactions to the skin and subcutaneous tissues, metabolic and nutritional disorders, and abnormalities of the hepatobiliary system.
Tenofovir is also known as tenofovir disoproxil fumarate tablets. It is indicated for the treatment of HIV-1 infection in adults and also for the treatment of chronic hepatitis B in adults and pediatric patients ≥12 years of age. However, it is contraindicated in patients with prior hypersensitivity to any of the ingredients in this drug.
There are some adverse reactions associated with the use of tenofovir, such as worsening of severe acute hepatitis B, new or worsening episodes of renal damage, lactic acidosis, severe hepatomegaly with steatosis, bone effects, and immune reconstitution inflammatory syndrome.
The above drugs should not be used without authorization, and should be used regularly under the guidance of a medical professional to avoid adverse effects.